Peter Senter

Biography

Dr. Senter is the Vice President of Chemistry at Seattle Genetics. His research surrounds targeted cancer therapy, with emphasis on monoclonal antibody-based delivery systems. The work from his laboratory provided the technology basis for brentuximab vedotin, a drug recently approved drug for the treatment of relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. Other areas of research include drug and prodrug design and synthesis, and novel fusion proteins for selective drug activation. Prior to joining Seattle Genetics in 1998, Dr. Senter held positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Cytokine Networks, and the Dana-Farber Cancer Institute. He serves as Senior Editor of Bioconjugate Chemistry, and as Affiliate Professor of Bioengineering at the University of Washington. Dr. Senter received a PhD in Chemistry from the University of Illinois and an AB in Biochemistry from the University of California, Berkeley.

Research Interest

Chemistr, genetics, Molecular Biology